Details of Disease

General Information of Disease (ID: DISZJDS2)

Disease Name	Fibromyalgia
Synonyms	fibromyalgia syndrome; fibromyalgia
Disease Class	MG30: Chronic pain
Definition	A chronic disorder of unknown etiology characterized by pain, stiffness, and tenderness in the muscles of neck, shoulders, back, hips, arms, and legs. Other signs and symptoms include headaches, fatigue, sleep disturbances, and painful menstruation.
Disease Hierarchy	DIS6SVEE: Syndromic disease DISRF1M2: Acute or chronic pain DISBBY0S: Idiopathic disease DISZJDS2: Fibromyalgia
ICD Code	ICD-11 ICD-11: MG30.01 ICD-10 ICD-10: M79.7 ICD-9 ICD-9: 729.1 Expand ICD-11 'MG30.01 Expand ICD-10 'M79.7 Expand ICD-9 729.1
Disease Identifiers	MONDO ID MONDO_0005546 MESH ID D005356 UMLS CUI C0016053 MedGen ID 42018 Orphanet ID 41842 SNOMED CT ID 203082005

Drug-Interaction Atlas (DIA) of This Disease

Drug-Interaction Atlas (DIA)

This Disease is Treated as An Indication in 7 Approved Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Desvenalfaxine succinate	DMJE6KO	Approved	Small molecular drug	[1]
Ibutamoren	DMFJ8LT	Approved	Small molecular drug	[2]
Indiplon	DMOPGHQ	Approved	Small molecular drug	[3]
Levetiracetam	DMTGDN8	Approved	Small molecular drug	[1]
Levomilnacipran	DMV26S8	Approved	Small molecular drug	[4]
Tropisetron	DMNSJ7V	Approved	Small molecular drug	[5]
Mirogabalin	DM5GIWZ	Registered	Small molecular drug	[6]
------------------------------------------------------------------------------------


⏷ Show the Full List of 7 Drug(s)

This Disease is Treated as An Indication in 11 Clinical Trial Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
TNX-102	DMO1234	Phase 3	Small molecular drug	[7]
AGN-XX/YY	DMMGAUK	Phase 2	Small molecular drug	[8]
ASP0819	DM6HJ3V	Phase 2	Small molecular drug	[9]
ASP8062	DMR1MIV	Phase 2	NA	[6]
ETS-6218	DMV96BY	Phase 2	NA	[10]
Flupirtine	DMPBV9D	Phase 2	Small molecular drug	[11]
IMC-1	DMKOIDK	Phase 2	NA	[6]
Interferon-alpha lozenge	DM8YF01	Phase 2	NA	[12]
NYX-2925	DM1P60V	Phase 2	NA	[6]
AD-337	DM8VQ1S	Phase 1	NA	[13]
SWT-06101	DMB3OBE	Phase 1	NA	[6]
------------------------------------------------------------------------------------


⏷ Show the Full List of 11 Drug(s)

This Disease is Treated as An Indication in 2 Discontinued Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Esreboxetine	DMTUHWM	Discontinued in Phase 2	Small molecular drug	[14]
PF-738502	DMUG6GR	Discontinued in Phase 1	NA	[15]
------------------------------------------------------------------------------------

This Disease is Treated as An Indication in 3 Investigative Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
PRTT-200	DM17ABJ	Investigative	NA	[16]
THA-902	DMKCY0X	Investigative	NA	[17]
Very low dose (VLD) cyclobenzaprine	DMUHEJ3	Investigative	NA	[18]
------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA) of This Disease

Molecular Interaction Atlas (MIA)

This Disease Is Related to 13 DTT Molecule(s)

Gene Name	DTT ID	Evidence Level	Mode of Inheritance	REF
ASIC3	TTLGDIS	moderate	Biomarker	[19]
OPRM1	TTKWM86	moderate	Genetic Variation	[20]
DRD3	TT4C8EA	Strong	Genetic Variation	[21]
ENPP2	TTSCIM2	Strong	Altered Expression	[22]
GRIN2B	TTN9D8E	Strong	Biomarker	[23]
HTR3A	TTPC4TU	Strong	Genetic Variation	[24]
HTR3B	TTR6K75	Strong	Biomarker	[24]
OPRD1	TT27RFC	Strong	Altered Expression	[25]
OPRL1	TTNT7K8	Strong	Biomarker	[26]
SCN9A	TT4G2JS	Strong	Genetic Variation	[27]
TRPV3	TT946IA	Strong	Genetic Variation	[28]
TACR1	TTZPO1L	Definitive	Biomarker	[29]
TRPV2	TTBECWA	Definitive	Biomarker	[30]
------------------------------------------------------------------------------------


⏷ Show the Full List of 13 DTT(s)

This Disease Is Related to 1 DME Molecule(s)

Gene Name	DME ID	Evidence Level	Mode of Inheritance	REF
CES2	DETHCPD	Limited	Genetic Variation	[31]
------------------------------------------------------------------------------------

This Disease Is Related to 21 DOT Molecule(s)

Gene Name	DOT ID	Evidence Level	Mode of Inheritance	REF
ADRM1	OTOU4EY6	Disputed	Biomarker	[32]
APOC1	OTA58CED	Strong	Altered Expression	[22]
CCL24	OT9LGHV0	Strong	Altered Expression	[33]
CNTN3	OTC1274J	Strong	Biomarker	[34]
CPQ	OTTNZNLD	Strong	Biomarker	[35]
DOCK11	OTFSTN6A	Strong	Genetic Variation	[36]
EMB	OT67E3Q1	Strong	Genetic Variation	[37]
MEFV	OTRJ6S6K	Strong	Altered Expression	[38]
MOS	OTNMQPFJ	Strong	Genetic Variation	[39]
MYT1L	OTV45MAS	Strong	Genetic Variation	[40]
NPS	OTEG25A2	Strong	Biomarker	[41]
PCSK1N	OT7ZRW2F	Strong	Altered Expression	[42]
PNOC	OTJEAADN	Strong	Genetic Variation	[26]
SCG2	OTXWUQQL	Strong	Altered Expression	[43]
TAC1	OTM842YW	Strong	Biomarker	[44]
TAC4	OTYWPPM3	Strong	Biomarker	[45]
TCP1	OT1MGUX9	Strong	Biomarker	[46]
TP53INP2	OT0GTBXO	Strong	Altered Expression	[25]
TSC22D3	OT03UM03	Strong	Altered Expression	[47]
GOLPH3	OTDLGYM3	Definitive	Biomarker	[48]
NRXN3	OTJ0I7HJ	Definitive	Biomarker	[30]
------------------------------------------------------------------------------------


⏷ Show the Full List of 21 DOT(s)

References

1	Emerging therapies for fibromyalgia. Expert Opin Emerg Drugs. 2008 Mar;13(1):53-62.
2	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5867).
3	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4221).
4	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7435).
5	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 260).
6	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
7	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800017946)
8	Clinical pipeline report, company report or official report of ACADIA Pharmaceuticals.
9	Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357.
10	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800031879)
11	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2598).
12	Clinical pipeline report, company report or official report of Amarillo Biosciences.
13	Emerging drugs for chemotherapy-induced emesis. Expert Opin Emerg Drugs. 2006 Mar;11(1):137-51.
14	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800040151)
15	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800025505)
16	The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.
17	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 686).
18	Pharmacological profile of the new potent neuroleptic ocaperidone (R 79,598). J Pharmacol Exp Ther. 1992 Jan;260(1):146-59.
19	ASIC3-dependent metabolomics profiling of serum and urine in a mouse model of fibromyalgia.Sci Rep. 2019 Aug 20;9(1):12123. doi: 10.1038/s41598-019-48315-w.
20	Identification of candidate genes associated with fibromyalgia susceptibility in southern Spanish women: the al-ndalus project.J Transl Med. 2018 Feb 27;16(1):43. doi: 10.1186/s12967-018-1416-8.
21	DRD3 Ser9Gly polymorphism is related to thermal pain perception and modulation in chronic widespread pain patients and healthy controls.J Pain. 2009 Sep;10(9):969-75. doi: 10.1016/j.jpain.2009.03.013. Epub 2009 May 23.
22	CSF levels of apolipoprotein C1 and autotaxin found to associate with neuropathic pain and fibromyalgia.J Pain Res. 2019 Oct 15;12:2875-2889. doi: 10.2147/JPR.S215348. eCollection 2019.
23	Anti-N-methyl-D-aspartate receptor antibodies are associated with fibromyalgia in patients with systemic lupus erythematosus: a case-control study.Clin Exp Rheumatol. 2017 May-Jun;35 Suppl 105(3):54-60. Epub 2017 Mar 10.
24	Mutational analysis of serotonin receptor genes: HTR3A and HTR3B in fibromyalgia patients.Clin Rheumatol. 2004 Aug;23(4):338-44. doi: 10.1007/s10067-004-0927-2. Epub 2004 May 7.
25	Skin cytokine expression in patients with fibromyalgia syndrome is not different from controls.BMC Neurol. 2014 Sep 22;14:185. doi: 10.1186/s12883-014-0185-0.
26	Nociceptin/orphanin FQ receptor modulates painful and fatigue symptoms in a mouse model of fibromyalgia.Pain. 2019 Jun;160(6):1383-1401. doi: 10.1097/j.pain.0000000000001513.
27	A SCN9A gene-encoded dorsal root ganglia sodium channel polymorphism associated with severe fibromyalgia.BMC Musculoskelet Disord. 2012 Feb 20;13:23. doi: 10.1186/1471-2474-13-23.
28	Polymorphisms of the TRPV2 and TRPV3 genes associated with fibromyalgia in a Korean population.Rheumatology (Oxford). 2016 Aug;55(8):1518-27. doi: 10.1093/rheumatology/kew180. Epub 2016 Apr 13.
29	The rs3771863 single nucleotide polymorphism of the TACR1 gene is associated to a lower risk of sicca syndrome in fibromyalgia patients.Clin Exp Rheumatol. 2015 Jan-Feb;33(1 Suppl 88):S33-40. Epub 2015 Mar 10.
30	Fibromyalgia: Genetics and epigenetics insights may provide the basis for the development of diagnostic biomarkers.Mol Pain. 2019 Jan-Dec;15:1744806918819944. doi: 10.1177/1744806918819944. Epub 2018 Nov 29.
31	Fibromyalgia, mood disorders, and intense creative energy: A1AT polymorphisms are not always silent.Neurotoxicology. 2012 Dec;33(6):1454-1472. doi: 10.1016/j.neuro.2012.03.001. Epub 2012 Mar 10.
32	Bidirectional association between migraine and fibromyalgia: retrospective cohort analyses of two populations.BMJ Open. 2019 Apr 8;9(4):e026581. doi: 10.1136/bmjopen-2018-026581.
33	Elevated Levels of Eotaxin-2 in Serum of Fibromyalgia Patients.Pain Res Manag. 2018 May 13;2018:7257681. doi: 10.1155/2018/7257681. eCollection 2018.
34	Extra Virgin Olive Oil Improves Oxidative Stress, Functional Capacity, and Health-Related Psychological Status in Patients With Fibromyalgia: A Preliminary Study.Biol Res Nurs. 2017 Jan;19(1):106-115. doi: 10.1177/1099800416659370. Epub 2016 Jul 26.
35	Altered Serum Oxytocinase and Enkephalin-Degrading Aminopeptidase Activities in Patients With Fibromyalgia.Biol Res Nurs. 2019 Jul;21(4):431-439. doi: 10.1177/1099800419854207. Epub 2019 May 26.
36	Association between catechol-O-methyl transferase gene polymorphisms and fibromyalgia in a Korean population: A case-control study.Eur J Pain. 2016 Aug;20(7):1131-9. doi: 10.1002/ejp.837. Epub 2016 Feb 5.
37	Prevalence of xenotropic murine leukemia virus-related virus infection in different risk populations in Spain.AIDS Res Hum Retroviruses. 2012 Sep;28(9):1089-94. doi: 10.1089/AID.2011.0149. Epub 2012 Feb 21.
38	SNPs in inflammatory genes CCL11, CCL4 and MEFV in a fibromyalgia family study.PLoS One. 2018 Jun 21;13(6):e0198625. doi: 10.1371/journal.pone.0198625. eCollection 2018.
39	Understanding the different relationships between mood and sleep disorders in several groups of non-oncological patients with chronic pain.Curr Med Res Opin. 2018 Apr;34(4):669-676. doi: 10.1080/03007995.2017.1384372. Epub 2017 Oct 25.
40	Genome-wide analysis of single nucleotide polymorphisms and copy number variants in fibromyalgia suggest a role for the central nervous system.Pain. 2014 Jun;155(6):1102-1109. doi: 10.1016/j.pain.2014.02.016. Epub 2014 Feb 26.
41	Towards a neurophysiological signature for fibromyalgia.Pain. 2017 Jan;158(1):34-47. doi: 10.1097/j.pain.0000000000000707.
42	Opioid-Induced Signaling and Antinociception Are Modulated by the Recently Deorphanized Receptor, GPR171.J Pharmacol Exp Ther. 2019 Oct;371(1):56-62. doi: 10.1124/jpet.119.259242. Epub 2019 Jul 15.
43	Immunohistochemical and molecular studies of serotonin, substance P, galanin, pituitary adenylyl cyclase-activating polypeptide, and secretoneurin in fibromyalgic muscle tissue.Arthritis Rheum. 1998 Sep;41(9):1689-94. doi: 10.1002/1529-0131(199809)41:9<1689::AID-ART21>3.0.CO;2-X.
44	Involvement of Substance P in the Analgesic Effect of Low-Level Laser Therapy in a Mouse Model of Chronic Widespread Muscle Pain.Pain Med. 2019 Oct 1;20(10):1963-1970. doi: 10.1093/pm/pnz056.
45	Mast Cells, Neuroinflammation and Pain in Fibromyalgia Syndrome.Front Cell Neurosci. 2019 Aug 2;13:353. doi: 10.3389/fncel.2019.00353. eCollection 2019.
46	Association of guanosine triphosphate cyclohydrolase 1 gene polymorphisms with fibromyalgia syndrome in a Korean population.J Rheumatol. 2013 Mar;40(3):316-22. doi: 10.3899/jrheum.120929. Epub 2013 Jan 15.
47	Glucocorticoid sensitivity in fibromyalgia patients: decreased expression of corticosteroid receptors and glucocorticoid-induced leucine zipper.Psychoneuroendocrinology. 2008 Jul;33(6):799-809. doi: 10.1016/j.psyneuen.2008.03.012. Epub 2008 May 12.
48	Comorbid fibromyalgia in migraine patients: clinical significance and impact on daily life.Neurol Res. 2019 Oct;41(10):909-915. doi: 10.1080/01616412.2019.1630164. Epub 2019 Jun 20.